Table 1.
Patient baseline characteristics and outcome
| Characteristic | Gene expression cohort n = 88 (%) | IHC cohort n = 131 (%) |
|---|---|---|
| Median follow-up time, mo (range) | 42 (12-164) | 55 (7-229) |
| Age (y) | ||
| Median (range) | 32 (16-84) | 29 (16-83) |
| <45 | 55 (62.5) | 100 (76) |
| ≥45 | 33 (37.5) | 31 (24) |
| Gender | ||
| Male | 43 (49) | 60 (46) |
| Female | 45 (51) | 71 (54) |
| Histological subtype | ||
| Nodular sclerosis | 65 (74) | 102 (78) |
| Mixed cellularity | 20 (23) | 22 (17) |
| Lymphocyte-rich | 2 (2) | 6 (4) |
| Unclassified cHL | 1 (1) | 1 (1) |
| Stage (Ann Arbor classification) | ||
| Limited (I-IIA) | 32 (36) | 56 (43) |
| Advanced (IIB-IV) | 55 (63) | 74 (56) |
| NA | 1 (1) | 1 (1) |
| EBV status | ||
| Negative | 46 (52) | 89 (68) |
| Positive | 26 (30) | 34 (26) |
| NA | 16 (18) | 8 (6) |
| Treatment | ||
| ABVD | 74 (84) | 112 (85) |
| BEACOPPesc | 4 (5) | 9 (7) |
| ABVD+BEACOPPesc | 4 (5) | 4 (3) |
| CHOP | 4 (5) | 4 (3) |
| Other | 2 (2) | 2 (2) |
| Radiotherapy* | 44 (50) | 78 (60) |
| Relapses | 25 (28) | 29 (22) |
| Deaths | 10 (11) | 10 (8) |
| cHL-related deaths | 8 (80) | 6 (60) |
| 5-y FFTF | 66% | 80% |
| 5-y OS | 85% | 91% |
NA, not assigned.
*
Including chemo- and radiotherapy and radiotherapy only.